News + Analysen
News + Adhoc
zugeh. Wertpapiere
Strukturierte Produkte
15.04.2019 22:04:56

Press Release: Novartis announces FDA filing -2-

particular, our expectations regarding such products could be affected

by, among other things, the uncertainties inherent in research and

development, including clinical trial results and additional analysis of

existing clinical data; regulatory actions or delays or government

regulation generally; global trends toward health care cost containment,

including government, payor and general public pricing and reimbursement

pressures; our ability to obtain or maintain proprietary intellectual

property protection; the particular prescribing preferences of

physicians and patients; general political and economic conditions;

safety, quality or manufacturing issues; potential or actual data

security and data privacy breaches, or disruptions of our information

technology systems, and other risks and factors referred to in Novartis

AG's current Form 20-F on file with the US Securities and Exchange

Commission. Novartis is providing the information in this press release

as of this date and does not undertake any obligation to update any

forward-looking statements contained in this press release as a result

of new information, future events or otherwise.

About Novartis

Novartis is reimagining medicine to improve and extend people's lives.

As a leading global medicines company, we use innovative science and

digital technologies to create transformative treatments in areas of

great medical need. In our quest to find new medicines, we consistently

rank among the world's top companies investing in research and

development. Novartis products reach more than 750 million people

globally and we are finding innovative ways to expand access to our

latest treatments. About 105 000 people of more than 140 nationalities

work at Novartis around the world. Find out more at www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at


For Novartis multimedia content, please visit


For questions about the site or required registration, please contact



[1] American Academy of Ophthalmology. Age-related macular degeneration

preferred practice patterns. Available at:


Accessed March 2019. [2] van Lookeren Campagne M, et al. Mechanisms of

age-related macular degeneration and therapeutic opportunities. J

Pathol. 2014; 232(2):151-64. doi: 10.1002/path.4266. [3]

ClinicalTrials.gov. Identifier NCT02307682. Available at

https://clinicaltrials.gov/ct2/show/NCT02307682 (link is external).

Accessed January 2019. [4] ClinicalTrials.gov. Identifier NCT02434328.

Available at https://clinicaltrials.gov/ct2/show/NCT02434328 (link is

external). Accessed January 2019. [5] Dugel P, et al. HAWK & HARRIER:

48-week results of 2 multi-centered, randomized, double-masked trials of

brolucizumab versus aflibercept for neovascular AMD. Presented at: The

American Academy of Ophthalmology 2017 Annual Meeting on November 10,

2017, New Orleans. [6] Dugel P, et al. Phase 3, randomized,

double-masked, multi-center trials of brolucizumab versus aflibercept

for neovascular AMD: 96-week results from the HAWK and HARRIER studies.

Presented at: The American Academy of Ophthalmology on October 27, 2018,

Chicago. [7] Escher D, et al. Single-chain antibody fragments in

ophthalmology. Oral presentation at EURETINA congress. 2015. Abstract.

[8] Nimz EL, et al. Intraocular and systemic pharmacokinetics of

brolucizumab (RTH258) in nonhuman primates. The Association for Research

in Vision and Ophthalmology (ARVO) annual meeting. 2016. Abstract 4996.

[9] Gaudreault J, et al. Preclinical pharmacology and safety of

ESBA1008, a single-chain antibody fragment, investigated as potential

treatment for age related macular degeneration. ARVO Annual Meeting

abstract. Invest Ophthalmol Vis Sci 2012;53:3025.

http://iovs.arvojournals.org/article.aspx?articleid=2354604 (link is

external). Accessed January 2019. [10] Tietz J, et al. Affinity and

Potency of RTH258 (ESBA1008), a Novel Inhibitor of Vascular Endothelial

Growth Factor A for the Treatment of Retinal Disorders. IOVS. 2015;

56(7):1501. [11] Qazi Y, et al. Mediators of ocular angiogenesis. J.

Genet. 2009;88(4):495-515. [12] Kim R. Introduction, mechanism of action

and rationale for anti-vascular endothelial growth factor drugs in

age-related macular degeneration. Indian J Ophthalmol.

2007;55(6):413-415. [13] Wong, W.L. et al. Global prevalence of

age-related macular degeneration and disease burden projection for 2020

and 2040: a systematic review and met analysis.

Lancet Glob Health

. 2014 Feb;2 (2):e106-16. [14] World Health Organization. Priority eye

diseases: Age-related macular degeneration. Available at

http://www.who.int/blindness/causes/priority/en/index7.html (link is

external). Accessed January 2019. [15] NHS Choices. Macular

Degeneration. Available at


(link is external). Accessed January 2019. [16] NHS Choices. Macular

Degeneration - Symptoms. Available at


(link is external). Accessed January 2019.

# # #

Novartis Media Relations

Central media line: +41 61 324 2200

E-mail: media.relations@novartis.com

Eric Althoff Martin DeBenedetto

Novartis Global Media Relations Director, Communications

+41 61 324 7999 (direct) +1 862 778-7619 (direct)

+41 79 593 4202 (mobile) +1 973 738-4104 (mobile)

eric.althoff@novartis.com martin.debenedetto@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Richard Pulik +1 862 778 3275

Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 862 778 3258

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

Media release (PDF): http://hugin.info/134323/R/2241647/884276.pdf

This announcement is distributed by West Corporation on behalf of West

Corporation clients.

The issuer of this announcement warrants that they are solely

responsible for the content, accuracy and originality of the information

contained therein.

Source: Novartis International AG via Globenewswire

--- End of Message ---

Novartis International AG

P.O. Box Basel Switzerland

WKN: 904278;ISIN: CH0012005267;


(END) Dow Jones Newswires

April 15, 2019 16:05 ET (20:05 GMT)

Analysen zu Novartis AGmehr Analysen

12:22 Novartis Neutral UBS AG
10:23 Novartis Underweight JP Morgan Chase & Co.
21.05.19 Novartis buy Kepler Cheuvreux
17.05.19 Novartis Neutral Credit Suisse Group
16.05.19 Novartis buy Jefferies & Company Inc.

Eintrag hinzufügen